SCYX Stock Recent News

JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Monday, August 15, 2022 to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022.

JERSEY CITY, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from the CANDLE 304s nested sub-study of ibrexafungerp for prevention of recurrent vulvovaginal candidiasis (RVVC) will be presented during the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update being held in Dublin, Ireland, July 15-20, 2022.

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.

SCYNEXIS, Inc. (NASDAQ:SCYX ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Marco Taglietti – President and Chief Executive Officer Christine Coyne – Chief Commercial Officer Dr. David Angulo – Chief Medical Officer Lawrence Hoffman – Interim Chief Financial Officer Debbie Etchison – Executive Director, Communications Conference Call Participants Michael Higgins – Ladenburg Thalmann Wayne Buchan – Cantor Fitzgerald Oren Livnat – H.C. Wainwright Operator Greetings and welcome to SCYNEXIS, Inc. First Quarter 2022 Earnings Conference Call.

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SCYNEXIS Inc (NASDAQ: SCYX) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients who are either intolerant to standard antifungal therapy or experience refractory.

SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the offering was not disclosed.

Data from studies evaluating ibrexafungerp in serious fungal infections will be presented Data from studies evaluating ibrexafungerp in serious fungal infections will be presented